Fangzhou Inc., a leader in AI-driven healthcare solutions, partnered with the Guangdong Provincial Liver Disease Institute at the 2025 Greater Bay Area International Liver Disease Forum to launch the "AI + Hepatitis Prevention and Control Training Center". This collaboration highlights the Company's pioneering efforts in leveraging artificial intelligence for advanced liver disease management.

Dr. Xie Fangmin, founder, chairman, and CEO of Fangzhou, commented, "Our role in establishing this training center highlights the Company's technological excellence and commitment to social responsibility. By integrating our AI innovations with the Institute's clinical expertise, we aim to improve access to high-quality hepatology care. Fangzhou will focus on smart screening tools and AI-assisted treatment protocols to set new standards in liver disease prevention and management."

Advancing AI-Assisted Liver Care and Patient Well-Being
The creation of the Training Center recognizes the Company's achievements in "AI-enabled full-cycle liver disease management", and also reflects the Company's expected role in continuing to apply cutting-edge AI technologies to advance liver disease prevention and treatment. As we work toward the goal of eliminating hepatitis as a major public health concern by 2030, the Company remains committed to its approach centered on patient well-being. Moving forward, the Company will continue to leverage AI as a core driver of innovation in the prevention and management of liver disease, while further enhancing standards for comprehensive full-cycle care. By deepening collaboration with research institutions, we aim to accelerate Guangdong's efforts to mitigate the impact of viral hepatitis on public health.